Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

What Do Hedge Funds Think of M&T Bank Corporation (MTB)?

Page 1 of 2

Is M&T Bank Corporation (NYSE:MTB) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research. Although there have been several high profile failed hedge fund picks, the consensus picks among hedge fund investors have historically outperformed the market after adjusting for known risk attributes. It’s not surprising given that hedge funds have access to better information and more resources to find the latest market-moving information.

M&T Bank Corporation (NYSE:MTB) shares haven’t seen a lot of action during the third quarter. Overall, hedge fund sentiment was unchanged. The stock was in 20 hedge funds’ portfolios at the end of the third quarter of 2015. At the end of this article we will also compare MTB to other stocks including Micron Technology, Inc. (NASDAQ:MU), Interactive Brokers Group, Inc. (NASDAQ:IBKR), and Skyworks Solutions Inc (NASDAQ:SWKS) to get a better sense of its popularity.

Follow M&t Bank Corp (NYSE:MTB)
Trade (NYSE:MTB) Now!

Now, let’s take a look at the fresh action encompassing M&T Bank Corporation (NYSE:MTB).

How are hedge funds trading M&T Bank Corporation (NYSE:MTB)?

According to Insider Monkey’s hedge fund database, Warren Buffett’s Berkshire Hathaway has the most valuable position in M&T Bank Corporation (NYSE:MTB), worth close to $656.3 million, corresponding to 0.5% of its total 13F portfolio. The second largest stake is held by PEAK6 Capital Management, managed by Matthew Hulsizer, which holds a $42.9 million call position; the fund has 0.2% of its 13F portfolio invested in the stock. Remaining peers that hold long positions include Cliff Asness’ AQR Capital Management, Mario Gabelli’s GAMCO Investors and Clint Carlson’s Carlson Capital.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!